Sellas Life Sciences Group, INC

SELLAS Life Sciences Group reported Q2 2026 results, highlighting progress in Phase 3 REGAL trial for GPS and Phase 2 for SLS009, with topline data expected Q4 2026, alongside a robust cash reserve of $138.3 million.

SELLAS Life Sciences Group, Inc. reported an estimated cash position of $138.3 million as of June 30, 2026, while also announcing an unfavorable arbitration decision regarding claims against 3D Medicines, Inc.

SELLAS Life Sciences Group has amended employment and severance agreements for its CEO, CFO, and Chief Development Officer.

SELLAS Life Sciences Group, Inc. reported on its Annual Meeting of Stockholders held on June 16, 2026, detailing voting outcomes on director re-elections, auditor ratification, equity plan amendments, executive compensation, and meeting adjournment.

SELLAS Life Sciences Group reports significant cash inflow from warrant exercises, bolstering its financial position.

SELLAS Life Sciences announced full-year 2025 financial results, reporting a strong cash position and significant progress in its pivotal Phase 3 REGAL trial and SLS009 clinical programs for AML.

SELLAS Life Sciences Group reports increased cash reserves and positive clinical trial developments for its cancer therapeutics, alongside continued operational losses.

SELLAS Life Sciences Group reports a net loss of $8.4 million for Q1 2026, with increased R&D spending and a robust cash balance of $107.1 million.

SELLAS Life Sciences Group, Inc. reported a reduced net loss and significantly increased cash reserves, driven by successful capital raises and positive clinical trial advancements for its SLS009 candidate.

SELLAS Life Sciences Group reports reduced net loss and operating expenses in Q2 2025, driven by progress in its oncology pipeline and recent financing activities, but faces ongoing liquidity challenges.

SELLAS Life Sciences Group reports its financial results for the first quarter of 2025, highlighting progress in its clinical trials and recent financial activities.

SELLAS Life Sciences reported a net loss of $24.1 million for the nine months ended September 30, 2024, while providing updates on its clinical programs for GPS and SLS009.

SELLAS Life Sciences Group files its 2024 10-K, highlighting clinical trial progress for GPS and SLS009 while reporting a net loss of $30.9 million.

SELLAS Life Sciences Group announces executive departures, provides updates on clinical trials for GPS and SLS009, and discloses financial details.

SELLAS Life Sciences Group reports that President and CEO Angelos M. Stergiou was granted 1,065,000 restricted stock units.

SELLAS Life Sciences Group, Inc. director John Varian received an award of 50,000 restricted stock units, vesting on December 1, 2026.

SELLAS Life Sciences Group Director Robert L. Van Nostrand received an award of 50,000 restricted stock units, vesting in December 2026.

SELLAS Life Sciences Group, Inc. Director David A. Scheinberg was awarded 50,000 restricted stock units vesting in December 2026.

SELLAS Life Sciences Group, Inc. awarded 300,000 restricted stock units to SVP, Chief Development Officer Dragan Cicic, vesting over several years.

SELLAS Life Sciences Group's CFO, John Thomas Burns, received an award of 300,000 restricted stock units, vesting over several years.

SELLAS Life Sciences Group announces its 2026 Annual Meeting of Stockholders to be held virtually on June 16, 2026, detailing proposals for director elections, auditor ratification, equity plan amendments, executive compensation, and meeting adjournment.

SELLAS Life Sciences Group, Inc. has issued a supplement to its 2025 Annual Meeting proxy statement, announcing the appointment of Baker Tilly US, LLP as its new independent auditor following a merger involving its previous auditor, Moss Adams LLP, while also noting a 'going concern uncertainty' in past financial statements.

SELLAS Life Sciences Group announces its 2025 Annual Meeting of Stockholders to be held on June 17, 2025, featuring proposals including director elections, auditor ratification, ESPP amendment, and executive compensation.

SELLAS Life Sciences Group will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to vote on director elections, auditor ratification, an employee stock purchase plan amendment, executive compensation, and other matters.

SELLAS Life Sciences Group, Inc. announces its 2024 Annual Meeting and provides details on voting proposals, including the election of directors, ratification of the accounting firm, and executive compensation.

SELLAS Life Sciences Group, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.

State Street Corporation has disclosed beneficial ownership of 7% of Sellas Life Sciences Group Inc.'s common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 9,666,278 shares, representing 5.19% of the class, in SELLAS Life Sciences Group Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in SELLAS Life Sciences Group Inc. due to an internal realignment.

Anson Funds and its affiliates have reported a 4.9% passive beneficial ownership stake in Sellas Life Sciences Group, Inc. as of December 31, 2025.

Highbridge Capital Management has reduced its beneficial ownership in SELLAS Life Sciences Group, Inc. from 6.0% to 3.7% through warrant exercises.

Anson Funds Management LP and affiliated entities have reported a 5.7% beneficial ownership stake in Sellas Life Sciences Group, Inc., totaling 6,032,938 shares.